Comparison of Two Biphasic Insulin Regimens
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Premixed Human Isophane Insulin Suspension + Human Insulin Injection
Premixed Insulin
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring diabetes mellitus type 2, glycemic control, glycated albumin, continuous glucose monitoring, fructosamine, glycated hemoglobin, insulin, premixed human insulin, premixed insulin analog
Eligibility Criteria
Inclusion Criteria:
- regular attendees of Outpatient Clinic of the Diabetes Centre of the 1st Department of Internal Medicine of University Hospital in Thessaloniki Greece
- The patients were on Premixed Human Insulin 30/70 twice daily with or without metformin
- baseline HbA1c<7%
Exclusion Criteria:
- the presence of type 1 Diabetes Mellitus
- stage 4 Chronic Kidney Disease
- use of antidiabetic medications other than insulin and metformin
- major cardiovascular event during the last six months
- acute illness and hospitalization during the last two weeks
- pregnancy
- absence of good metabolic control assessed with self-monitoring of blood glucose during the week before entering the study (>20% of the measurements <80mg/dl or >130mg/dl)
- inability of the patients to understand the study procedures and sign the consent form
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Premixed Insulin
Premixed insulin
Arm Description
Premixed Human Insulin
Premixed Insulin Analog
Outcomes
Primary Outcome Measures
Change in average blood glucose
average blood glucose (mg/dl) from continuous glucose monitoring
Glycated Albumin
levels of glycated albumin (%) in serum
Fructosamine
levels of fructosamine (μmol/L) in serum
Secondary Outcome Measures
Daily Insulin requirements
change in total daily dose of insulin (u)
nocturnal average blood glucose
change in nocturnal average blood glucose
Time in range
change in time in range (% and minutes) from continuous glucose monitoring
time above 180
change in time above 180 (% and minutes) from continuous glucose monitoring
time below 70
change in time below 70 (% and minutes) from continuous glucose monitoring
Full Information
NCT ID
NCT04726657
First Posted
January 23, 2021
Last Updated
January 23, 2021
Sponsor
Aristotle University Of Thessaloniki
Collaborators
University Hospital Tuebingen
1. Study Identification
Unique Protocol Identification Number
NCT04726657
Brief Title
Comparison of Two Biphasic Insulin Regimens
Official Title
Comparison of Two Biphasic Insulin Regimens in Well-controlled Patients With the Use of Continuous Glucose Monitoring and New Glycemic Control Indices
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
January 18, 2016 (Actual)
Primary Completion Date
February 3, 2020 (Actual)
Study Completion Date
February 3, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aristotle University Of Thessaloniki
Collaborators
University Hospital Tuebingen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
Comparison of Two Biphasic Insulin Regimens in Well-controlled Patients With the Use of Continuous Glucose Monitoring and New Glycemic Control Indices
Detailed Description
A cross-over study of 36 well controlled people with type 2 Diabetes Mellitus who underwent 7-day Continuous Glucose Monitoring with Premixed Human Insulin 30/70 and subsequently with Biphasic Aspart 30.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
diabetes mellitus type 2, glycemic control, glycated albumin, continuous glucose monitoring, fructosamine, glycated hemoglobin, insulin, premixed human insulin, premixed insulin analog
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Cross-over
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Premixed Insulin
Arm Type
Active Comparator
Arm Description
Premixed Human Insulin
Arm Title
Premixed insulin
Arm Type
Active Comparator
Arm Description
Premixed Insulin Analog
Intervention Type
Drug
Intervention Name(s)
Premixed Human Isophane Insulin Suspension + Human Insulin Injection
Other Intervention Name(s)
premixed human insulin
Intervention Description
premixed human insulin
Intervention Type
Drug
Intervention Name(s)
Premixed Insulin
Other Intervention Name(s)
Biphasic Aspart 30
Intervention Description
Premixed Insulin Analog Biphasic Aspart 30
Primary Outcome Measure Information:
Title
Change in average blood glucose
Description
average blood glucose (mg/dl) from continuous glucose monitoring
Time Frame
7 days
Title
Glycated Albumin
Description
levels of glycated albumin (%) in serum
Time Frame
7 days
Title
Fructosamine
Description
levels of fructosamine (μmol/L) in serum
Time Frame
7 days
Secondary Outcome Measure Information:
Title
Daily Insulin requirements
Description
change in total daily dose of insulin (u)
Time Frame
7 days
Title
nocturnal average blood glucose
Description
change in nocturnal average blood glucose
Time Frame
7 days
Title
Time in range
Description
change in time in range (% and minutes) from continuous glucose monitoring
Time Frame
7 days
Title
time above 180
Description
change in time above 180 (% and minutes) from continuous glucose monitoring
Time Frame
7 days
Title
time below 70
Description
change in time below 70 (% and minutes) from continuous glucose monitoring
Time Frame
7 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
regular attendees of Outpatient Clinic of the Diabetes Centre of the 1st Department of Internal Medicine of University Hospital in Thessaloniki Greece
The patients were on Premixed Human Insulin 30/70 twice daily with or without metformin
baseline HbA1c<7%
Exclusion Criteria:
the presence of type 1 Diabetes Mellitus
stage 4 Chronic Kidney Disease
use of antidiabetic medications other than insulin and metformin
major cardiovascular event during the last six months
acute illness and hospitalization during the last two weeks
pregnancy
absence of good metabolic control assessed with self-monitoring of blood glucose during the week before entering the study (>20% of the measurements <80mg/dl or >130mg/dl)
inability of the patients to understand the study procedures and sign the consent form
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Triantafyllos Didangelos, Assoc. Prof.
Organizational Affiliation
AHEPA Hospital Aristotle University Of Thessaloniki
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Upon request
Learn more about this trial
Comparison of Two Biphasic Insulin Regimens
We'll reach out to this number within 24 hrs